HUBUNGAN NILAI LIMFOSIT ABSOLUT DAN RASIO NETROFIL LIMFOSIT DENGAN LUARAN PADA PASIEN COVID-19 DI RSUP DR. M. DJAMIL PADANG
| dc.contributor.advisor | Irvan, Medison | |
| dc.contributor.author | Muhammad, Hari Nandi Pinto | |
| dc.date.accessioned | 2026-09-24T23:23:00Z | |
| dc.date.issued | 2021-11-10 | |
| dc.description | Dr.Irvan Medison, Sp.P(K). FISR. FAPSR | |
| dc.description.abstract | Latar belakang: Nilai limfosit absolut (ALC) dan nilai rasio netrofil limfosit (NLR) menjadi salah satu parameter yang memiliki nilai aplikasi klinis dalam memprediksi perkembangan COVID-19. Limfopenia dianggap sebagai penanda awal diagnosis COVID-19 dan neutrofil yang dipicu oleh faktor inflamasi seperti IL-6, IL-8, TNF-ɑ diproduksi oleh limfosit dan sel endotel yang terkait pada infeksi virus. Tujuan dari penulisan ini adalah untuk mengetahui hubungan nilai rasio netrofil limfosit dan limfosit absolut dengan luaran pasien COVID-19 terkonfirmasi di RSUP Dr. M. Djamil Padang. Metode: Penelitian analitik observasional dengan pendekatan kohort retrospektif pada pasien COVID-19 terkonfirmasi yang dirawat di RSUP DR M Djamil Padang. Data diambil dari bulan Januari 2021 sampai dengan Maret 2021. Analisis Chi-Square/Fisher Exact Test dengan nilai p value < 0.05 dihitung untuk melihat hubungan nilai rasio netrofil limfosit dan limfosit absolut dengan luaran pasien COVID-19 di RSUP Dr M Djamil Padang. Penelitian menggunakan analisis multivariat dengan logistic regression untuk menilai pengaruh ALC dan NLR terhadap faktor resiko luaran pada pasien covid 19. Hasil: Karakteristik pasien sebagian besar adalah berusia lebih dari 50 tahun, (64.3%), perempuan (52.2%), tidak ada limfopenia (44.9%), dan nilai NLR ≥ 3,13 (51.1%). Pasien dengan limfopenia berat dan peningkatan NLR akan memiliki tingkat kematian yang lebih tinggi dengan nilai OR 1.56 (95% CI 1.31-1.99) dan. OR 2.64 (95% CI 1.48-4.69).Analisis multivariat mendapatkan nliai NLR sebagai faktor resiko yang berperan terhadap luaran OR 2,36 (1,74-4,74) Kesimpulan: Nilai NLR sabagai faktor resiko independen mortaliti | |
| dc.identifier.uri | https://ailib.my.id/handle/123456789/71603 | |
| dc.language.iso | id | |
| dc.publisher | Universitaas Andalas | |
| dc.subject | COVID-19 | |
| dc.subject | ALC | |
| dc.subject | NLR | |
| dc.subject | faktor resiko | |
| dc.subject | hasil luaran | |
| dc.subject.classification | RB Pathology | |
| dc.title | HUBUNGAN NILAI LIMFOSIT ABSOLUT DAN RASIO NETROFIL LIMFOSIT DENGAN LUARAN PADA PASIEN COVID-19 DI RSUP DR. M. DJAMIL PADANG | |
| dc.type | Thesis | |
| dcterms.dateSubmitted | 2022-01-26 | |
| dcterms.references | 1. Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Machado LFA, et al. Origin, Transmission, Diagnosis and Management of Coronavirus Disease 2019 (COVID-19). Postgrad Med J. 2020;96:753-8. 2. Yuce M, Filiztekin E, Ozkaya KG. COVID-19 Diagnosis – A Review of Current Methods. Biosensors and Bioelectronics.2021. 3. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12 (372):1-17. 4. Ramadhan P.2020.”Diagnosis COVID-19”. Fakultas Kedokteran. Universitas Sriwijaya. Palembang. 5. Susilo A, Rumende CM, Pitoyo CW,Santoso WD, Yulianti M,Herikurniawan, dkk. Coronavirus Disease 2019 : Tinjauan Literatur Terkini. Jurnal Penyakit Dalam Indonesia.2020;7(1):45-67. 6. World Health Organization.Coronavirus Disease (COVID-19) Pandemic.2021[updated 2021 March 6th; cited 2021 March 6th 7. Kementrian Kesehatan Republik Indonesia. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19) Juli 2020. Jakarta : Kementrian Kesehatan Republik Indonesia; 2020. 8. World Health Organization.Coronavirus Disease (COVID-19) Pandemic Update on Coronavirus Disease in Indonesia. 2021 [updated 2021 March 4th; cited 2021 March 6th 9. Fatoni AZ, Rakhmatullah R. Acute Respiratory Distress Syndrome (ARDS) pada Pneumonia COVID-19. Journal of Anaesthesia and Pain.2021;2(1):11-24. 10. Khourssaji M, Chapelle V, Evenepoel A, Belkhir L, Yombi JC, Dievoet MAV, et al. A biological profile for diagnosis and outcome of COVID-19 patient. Clinical Chemistry and Laboratory Medicine. 2020;58(12):2141-50 11. Sun S, Cai X, Wang H, He G, Lin Y, Lu B, et al. Abnormalities of Peripheral Blood System in Patients with COVID-19 in Wenzhou, China. Clinica Chimica Acta507. 2020:174-80. 12. Usulan Panduan Pemeriksaan Laboratorium COVID-19. Perhimpunan Dokter Spesialis Patologi Klinik dan Kedokteran Laboratorium Indonesia. 2020. 13. Jin A, Yan B, Feng D, Xu B, Liang L,Guo C. Clinical Characteristik of Patients Diagnosed with COVID-19 in Beijing. Biosafety and Health.2020. 14. Circullo A, Borghetti A, Verne LZD, Tosoni A,Lombardi F, Garcovich M, et al. Neutrophil-to-Lymphocyte Rasio and Clinical Outcome in COVID-19: A Report from the Italian Front Line. International Journal of Antimicrobial Agents.2020;18(56):1-3. 15. Jimeno S, Ventura PS, Castellano J M, García-Adasme S I, Miranda M, Touza P. Prognostic implications of neutrophil-lymphocyte Rasio in COVID-19. Eur. J. Clin. Invest. 2021;51:e13404 16. Liu Y, Du X, Chen J. Neutrophil-to-lymphocyte Rasio as an independent risk factor for mortality inhospitalized patients with COVID-19. J Infect. 2020;81(1):e6–12. 17. Liu J, Li H, Luo M, Liu J, Wu L, Lin X, et al. Lymphopenia Predicted Illness Severity and Recovery in Patiens with COVID-19 : A Single-center, Retrospective Study. PLOS ONE. Published On November 18,2020. 18. Selanoo Y, Widaningsih Y, Esa T, Arif M. Analysis of Neurtophil Lymphocyte Ratio and Absolute Lymphocyte Count as Predictors of Severity of COVID-19 Patient. Indonesiian Journal of Clinical Pathology and Medical Laboratory.2021;27(2):184-9 19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:498-504 20. Handayani D, Hadi DR,Isbaniah F, Burhan E, Agustin H. Penyakit Virus Coronoa 2019. Jurnal Respirologi Indonesia.2020;40(2):119-29. 21. Azer.SA. COVID-19 : Pathophysiology, Diagnosis, Complication, Investigational Theraphy. Departement of Medical Education.2020;1-8 22. Brenneis R. COVID-19 : Pathophysiology and Clinical Findings. 23. Cascella M, Rajnik M, Cuomo A, Dulebohn S C, Napoli R D. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls Publishing. 2021 24. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database of Systematic Reviews. 2020 25. Wiersinga JW, Rhodes A, Cheng AC, Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782-93. 26. Grace G. Manifestasi Klinis dan Perjalanan Penyakit pada Pasien Covid-19. Majority. 2020; 9(1):51-2. 27. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 07;323(13):1239-42. 28. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Geneva: World Health Organization; 2020. 29. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New Engl J Med. 2020;1708-19. 30. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;1-6. 31. Büyükkaya E, Karakaş M, Karakaş E, Akçay A, Tanboğa I, Kurt M. Correlation of neutrophil to lymphocyte Rasio with the presence and severity of metabolic syndrome. Clin Appl Thromb Hemost 2014:20;159- 63. 32. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID‐19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846‐8. 33. Amanda A D. Rasio Neutrofil-Limfosit pada Covid-19; Sebuah Tinjauan Literatur. Wellness and Healthy Magazine. 2020:2(2);219-23. 34. Lagunas‐Rangel, F. A. Neutrophil‐to‐lymphocyte Rasio and lymphocyte‐to‐C‐reactive. protein Rasio in patients with severe coronavirus disease 2019 (COVID‐19): A meta‐analysis. Journal of medical virology. 2020;1-2. 35. Imran M M, Ahmad U, Usman U, Ali M, Shaukat A, Gul N. Neutrophil/lymphocyte Rasio-A marker of COVID-10 pneumonia severity. Int J Clin Pract. 2021;1-7. 36. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–39 37. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-Reactive Protein, Procalcitonin, D-Dimer, and Ferritin in Severe Coronavirus Disease-2019: A Meta-Analysis. SAGE Journals.2020:1-14 38. Magro G. SARS-CoV-2 and COVID-19: Is Interleukin-6 (IL-6) the ‘Culprit Lesion’ of ARDS Onset? What is there besides Tocilizumab?SGP13-Fc. Cytokine:X.2020. 39. Melenotte C, Silvin A, Goubet AG, Lahmar I, Dubuisson A,Zumla A, et al. Immune respon during COVID infection.Oncoimmunology.2020;9(1): 23p 40. Letter to the Editor. Lymphopenia during the COVID-19 Infection : What it shows and what can be learned. Immunology Letters.2020; 225: 31-32. 41. Mehta P, McAuley DF, Brown M, et al. COVID‐19: consider cytokine stormsyndromesandimmunosuppression. Lancet. 2020;395(10229):1033‐4. 42. Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID‐19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020;22(2):95‐7. 43. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid‐19. N Engl J Med. 2020;382(25):e102 44. Illg Z, Muller G, Mueller M, Nippert J, Allen B. Analysis of absolute lymphocyte count in patients with COVID-19. Am J Emerg Med. 2021;46:16-9. 45. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007;109: 3812–9. 46. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal. Transduct Target Ther. 2020; 5: 33. 47. Bermejo-Martin JF, Almansa R, Menéndez R, Mendez R, Kelvin DJ, Torres A. Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. J Infect. 2020;80: e23–4. 48. Yang L, Jin J, Luo W, Gan Y, Chen B, Li W. Risk factors for predicting mortality of COVID-19 patients: A systematic review and meta-analysis. PLoS ONE. 2020;15(11): e0243124. 49. Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study. Cancers (Basel). 2021;13(3):471. 50. Wagner J, DuPont A, Larson S, Cash B, Farooq A. Absolute lymphocyte count is a prognostic marker in Covid-19: A retrospective cohort review. Int J Lab Hematol. 2020;42(6):761-5 51. Huang G, Kovalic AJ, Graber CJ. Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity. Emerg Infect Dis. 2020;26(8):1839–41. 52. Wang S, Fu L, Huang K, Han J, Zhang R, Fu Z. Neutrophil-to-lymphocyte Rasio on admission is an independent risk factor for the severity and mortality in patients with coronavirus disease 2019. J Infect. 2021;82(2):e16-8. 53. Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J. Leukoc. Biol. 2020;108(1):17–41 54. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID‐19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):1-56 55. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C. Neutrophil-to-lymphocyte Rasio predicts critical illness patients with 2019 coronavirus disease in the early stage. Journal of Translational Medicine. 2020;18(1):206-18. 56. Jain V, Yuan JM. Predictive Symptoms and Comorbidities for Severe COVID-19 and Intensive Care Unit Admission: A Systematic Review and Meta-analysis. International Journal of Public Health.2020. 57. Edis E C. Chronic Pulmonary Diseases and COVID-19 . Turk Thorac J 2020; 21(5): 345-9 58. Clerkin K J, Fried J A, Raikhelkar J, Sayer G, Griffin J M, Masoumi A, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020;141:1648–55. 59. Momtazmanesh S, Shobeiri P, Hanaei S, Mahmoud-Elsayed H, Dalvi B, Rad E M. Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool. The Egyptian Heart Journal. 2020:72(41);1-17 60. Ruocco G. Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity. International Journal of Infectious Diseases.2020;373–5. 61. Schiffrin E L, Flack J M, Ito S, Muntner P, Webb R C. Hypertension and COVID-19. American Journal of Hypertension. 2020: 33(5);373. 62. Ejaz H, Alsrhani A, Zafar A, Javed H, junaid K, Abdalla AE, et al. COVID-19 and Comorbidities: Deleterious Impact on Infected Patients. Journal of Infection and Public Health.2020:1833-9 63. Hassanein M, Radhakrishnan Y, Vachharajani T, Vachharajani VT, Augustine J, Demirjian S, et al. COVID-10 and the Kidney. Cleveland Clinic Journal of Medicine.2020;87(10):619-31 64. Wu J, Song S, Cao HC, Li LJ. Liver Disease in COVID-19: Etiology, Treatment and Prognosis. World Journal of Gastroenterology.2020;26(19):2286-93 65. Han HJ, Nwagwu C, Anyim O, Ekweremadu C, San K. COVID-19 and Cancer: from Basic Mechanisms to Vaccine Development Using Nanotechnology. International Immunopharmacology.2021. 66. Moujaess E, Kourie HR, Ghosn M. Cancer Patients and Research during COVID-19 Pandemic: A Systematic Review of Current Evidence. Critical Reviews in Oncology/Hematology.2020. 67. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo W, Susilo A, et al. Pedoman Tatalaksana COVID-19. Third. Jakarta. 2020 68. World Health Organization. Criteria for Releasing COVID-19 Patient from Isolation. 2020. 69. Burhan E. Tatalaksana klinis COVID-19. Satgas Waspada dan Siaga COVID-19 PB IDI.2020 70. Suendra H, Elyazar I, Djaafara B, Ekawati L, Saraswati K, Adrian V. Oktavia D. Clinical characteristics and motality associated with COVID-19 in Jakarta: a hospital based retropctive cohort study.The Lancet Regional Health.2021;9:100-8. 71. Rashedi J, Poor BM, Asgharzadeh V, Pourostadi M, Kafll HS, Vegarl A, Khosroshahl, et al. Risk Factors for COVID-19. Le Infezioni in Medicina.2020;4 :469-74 72. Shang W, Dong J, Ren Y, Tian M, Li W, Hu J, et al. The Value of Clinical Parameters in Predicting theSeverity of COVID-19. 2020: 1-17. 73. Grasseli G, Greco M, Zanella A,Albano G,Antonelli M, Bellani G, et al. Risk Factors Associated with Mortality Among Patients with COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Internal Medicine. Published Online July 15. 74. Wang JB, Wang HT, Wang LS, Li LP, Xv J, Xv C, et al. Epidemiological and Clinical Characteristics of Fifty-six Cases of COVD-19 in Liaoning Province, China. World Journal of Clinical Cases. 2020;8(21):5188-202 75. Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, et al. Factors Associated with Prolonged Viral RNA Shedding in Patients with COVID-19.2020:1-24 76. Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, Wright O, et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS ONE. 2021; 16(3): 1-12 77. Cheng B, Hu J, Zuo X, Yang G, Shi X, Deng A. Predictors of progression from moderate to severe coronavirus disease 2019: a retrospective cohort. Clinical Microbiology and Infection. 2020; 26 (10); 1400-05 78. Zhang J, Wang M, Zhao M, Guo S, Xu Y, Ding W, et al. The Clinical Characteristics and Prognosis Factors of Mild-Moderate Patients With COVID-19 in a Mobile Cabin Hospital: A Retrospective, Single-Center Study. Frontiers in Public Health. 2020; 8; 1-11 79. Ruiz SJ, Ventura PS, Vazquez JMC, Adasme SIG, Garcia MM, Pol PT, et al. Prognostic Implications of Neutrophil-Lymphocyte Ratio in COVID-19. Wiley.2020:1-9 80. Gao YD, Ding M, Dong X, Zhang JJ, Azkur AK, Azkur D, et al. Risk Factors for Severe and Critically Ill COVID-19 Patients: 81. Zhu L, She ZG, Cheng X, Guo J, Zhang BH, Li H. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism. 2020; 31: 1068-77 82. Guo T, Fan Y, Chen M, Wu X, ZHang L, He T, et al. Cardiovaskular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020: 1-8. 83. Mohamed NE, Benn EKT, Astha V, Okhawere KE, Korn TG, Nkemdirim W, et al. Association between chronic kidney disease and COVID 19 related mortality in New York. World Journal of Urology. 2021;1-7 84. Gibertoni D, Reno C, Rucci P, Fantini MP, Buscaroli, Mosconi G, et al. COVID-19 incidence and mortality in non-dialysis chronic kidney disease patients. PLOS ONE. 2021;1-11 85. Ozturk S, Ozturk S, Turgutalp K, Arici M, Odabas AR, Altiparmak MR, Aydin Z. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dial Transplant. 2020;35:2083-95 86. Fillmore NR, La J, Szalat RE, tuck DP, Nguyen V, Yildirim C, et al. Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. JNCI J Natl Cancer Inst. 2021; 11(6): 691-2 87. Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med. 2021;18(1): 298-307 88. Kong X, Qi Y, Huang J, Zhao Y, Zhan Y, Qin X, et al. Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global data. Cancer Letters. 2021; 30–46 89. Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020; 17(3): 519–27. 90. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Disease are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysisi. Aging and Disease. 2020; 11(3): 668-78 91. Sharma A, Jaiswal P, Kerakhan Y, Sarav anan L, Murtaza Z, Zargham A, et al. Liver disease and outcomes among COVID-19 hospitalized patients – A systematic review and meta-analysis. Annals of Hepatology. 2021;1-8 92. Lin J, Bao B, Khurram N A, Halsey K, Choi J W, Wang L, et al. Chronic liver disease not a signifcant comorbid condition for COVID 19. Scientific Reports. 2021:11;1-6 93. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA. Published Online April 2020. DOI : 10.1001/jama.2020.6775 94. Biamonte F, Botta C, Mazzitelli M, Rotundo S, Trecarichi EM, Foti D, et al. Combined lymphocyte/monocyte count, D‑dimer and iron status predict COVID‑19 course and outcome in a long‑term care facility. Journal of Translational Medicine. 2021: 19(79); 1-10 95. Terpos E, Stathopoulos LN, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological Findings and Complications of COVID-19. Am J Hematol. 2020; 1-14. 96. Miesbach W, Makris M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rational for Anticoagulation. Clinical and Applied Thrombosis/Hemostasis. 2020: 20; 1-7 97. Du P, Li D, Wang A, Shen S, Ma Z, Li X. A Systematic Review and Meta-Analysis of Risk Factors Associated with Severity and Death in COVID-19 Patients. Canadian Journal of Infectious Diseases and Medical Microbiology. 2021;1-21 98. Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLOS ONE. 2021;1-21 99. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical Characteristics of 113 Deceased Patients with Coronavirus disease 2019: Retrospective Study. BMJ. 2020;368: m1091: 1-14 100. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis.Intervirology 2021;64:36–47 Rudiansyah M, Nur’amin HW, Lubis L, Bandiara R, Roesli RMA, Rachmadi D. COVID-19 and Kideny Disease in Indonesia. Sys Rev Pharm 2020;11(7):435-42 | |
| local.eprints.dir | disk0/00/09/75/53 | |
| local.eprints.division | S2 | |
| local.eprints.id | 97553 | |
| local.eprints.type | thesis/masters | |
| local.eprints.uri | http://scholar.unand.ac.id/97553/ | |
| local.fakultas | Pascasarjana (S2) | |
| local.thesis.level | Tesis |
